Rapid screening of novel agents for combination therapy in sarcomas

Sarcoma

Volumn 2013, Issue , 2013, Pages

  Cubitt, Christopher L ^a   Menth, Jiliana ^a   Dawson, Jana ^a   Martinez, Gary V ^a   Foroutan, Parastou ^a   Morse, David L ^a   Bui, Marilyn M ^a   Letson, G Douglas ^a   Sullivan, Daniel M ^a   Reed, Damon R ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; BELINOSTAT; CISPLATIN; CYTARABINE; DASATINIB; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GYRASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; OBATOCLAX; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; RIDAFOROLIMUS; SARACATINIB; SELUMETINIB; SORAFENIB; TOPOTECAN; TRICIRIBINE; VELIPARIB; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG SCREENING; EWING SARCOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA CELL;

EID: 84887428563     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2013/365723     Document Type: Article

References (48)

1. Reed D., Altiok S., Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine. Cancer Control 2011 18 3 188 195 2-s2.0-79959372348
2. Blanke C. D., Rankin C., Demetri G. D., Ryan C. W., Von Mehren M., Benjamin R. S., Raymond A. K., Bramwell V. H. C., Baker L. H., Maki R. G., Tanaka M., Hecht J. R., Heinrich M. C., Fletcher C. D. M., Crowley J. J., Borden E. C., Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Journal of Clinical Oncology 2008 26 4 626 632 2-s2.0-39149127634 10.1200/JCO.2007.13.4452 (Pubitemid 351264358)
3. Van Glabbeke M., Verweij J., Judson I., Nielsen O. S., Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. European Journal of Cancer 2002 38 4 543 549 2-s2.0-0036189675 10.1016/S0959-8049(01)00398-7 (Pubitemid 34185394)
4. Tariq Mahmood S., Agresta S., Vigil C. E., Zhao X., Han G., D'Amato G., Calitri C. E., Dean M., Garrett C., Schell M. J., Antonia S., Chiappori A., Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. International Journal of Cancer 2011 129 8 1963 1969 2-s2.0-80051631789 10.1002/ijc.25843
5. Chou T.-C., Talalay P., Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 1984 22 27 55 2-s2.0-0021118703
6. Siegel D., Hussein M., Belani C., Robert F., Galanis E., Richon V. M., Garcia-Vargas J., Sanz-Rodriguez C., Rizvi S., Vorinostat in solid and hematologic malignancies. Journal of Hematology and Oncology 2009 2, article 31 2-s2.0-69249209745 10.1186/1756-8722-2-31
7. Fouladi M., Park J. R., Stewart C. F., Gilbertson R. J., Schaiquevich P., Sun J., Reid J. M., Ames M. M., Speights R., Ingle A. M., Zwiebel J., Blaney S. M., Adamson P. C., Pediatric phase I trial and pharmacokinetic study of vorinostat: a children's oncology group phase I consortium report. Journal of Clinical Oncology 2010 28 22 3623 3629 2-s2.0-77955900071 10.1200/JCO.2009.25. 9119
8. Wilhelm S. M., Adnane L., Newell P., Villanueva A., Llovet J. M., Lynch M., Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics 2008 7 10 3129 3140 2-s2.0-55749088393 10.1158/1535-7163.MCT-08- 0013
9. Lombardo L. J., Lee F. Y., Chen P., Norris D., Barrish J. C., Behnia K., Castaneda S., Cornelius L. A. M., Das J., Doweyko A. M., Fairchild C., Hunt J. T., Inigo I., Johnston K., Kamath A., Kan D., Klei H., Marathe P., Pang S., Peterson R., Pitt S., Schieven G. L., Schmidt R. J., Tokarski J., Wen M.-L., Wityak J., Borzilleri R. M., Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4- (2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5- carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. Journal of Medicinal Chemistry 2004 47 27 6658 6661 2-s2.0-19944428353 10.1021/jm049486a (Pubitemid 40053752)
10. Hantschel O., Rix U., Superti-Furga G., Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leukemia and Lymphoma 2008 49 4 615 619 2-s2.0-42049123098 10.1080/10428190801896103 (Pubitemid 351517198)
11. Olivieri A., Manzione L., Dasatinib: a new step in molecular target therapy. Annals of Oncology 2007 18 6 vi42 vi46 2-s2.0-35748952533 10.1093/annonc/mdm223
12. Berndt N., Yang H., Trinczek B., Betzi S., Zhang Z., Wu B., Lawrence N. J., Pellecchia M., Schönbrunn E., Cheng J. Q., Sebti S. M., The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. Cell Death and Differentiation 2010 17 11 1795 1804 2-s2.0-77957833800 10.1038/cdd.2010.63
13. Garrett C. R., Coppola D., Wenham R. M., Cubitt C. L., Neuger A. M., Frost T. J., Lush R. M., Sullivan D. M., Cheng J. Q., Sebti S. M., Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Investigational new drugs 2011 29 6 1381 1389 2-s2.0-80054809459
14. Yap T. A., Yan L., Patnaik A., Fearen I., Olmos D., Papadopoulos K., Baird R. D., Delgado L., Taylor A., Lupinacci L., Riisnaes R., Pope L. L., Heaton S. P., Thomas G., Garrett M. D., Sullivan D. M., De Bono J. S., Tolcher A. W., First-in-man clinical trial of the oral pan-AKT inhibitor MK-206 in patients with advanced solid tumors. Journal of Clinical Oncology 2011 29 35 4688 4695 2-s2.0-83255162603 10.1200/JCO.2011.35.5263
15. Neale G., Su X., Morton C. L., Phelps D., Gorlick R., Lock R. B., Reynolds C. P., Maris J. M., Friedman H. S., Dome J., Khoury J., Triche T. J., Seeger R. C., Gilbertson R., Khan J., Smith M. A., Houghton P. J., Molecular characterization of the pediatric preclinical testing panel. Clinical Cancer Research 2008 14 14 4572 4583 2-s2.0-51649092873 10.1158/1078-0432.CCR-07-5090
16. Houghton P. J., Morton C. L., Tucker C., Payne D., Favours E., Cole C., Gorlick R., Kolb E. A., Zhang W., Lock R., Carol H., Tajbakhsh M., Reynolds C. P., Maris J. M., Courtright J., Keir S. T., Friedman H. S., Stopford C., Zeidner J., Wu J., Liu T., Billups C. A., Khan J., Ansher S., Zhang J., Smith M. A., The pediatric preclinical testing program: description of models and early testing results. Pediatric Blood & Cancer 2007 49 7 928 940 2-s2.0-34447249881 10.1002/pbc.21078 (Pubitemid 350022448)
17. Gorlick R., Maris J. M., Houghton P. J., Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program. Pediatric Blood & Cancer 2012 59 3 518 524 10.1002/pbc.23412
18. Keir S. T., Maris J. M., Lock R., Kolb E. A., Gorlick R., Carol H., Morton C. L., Reynolds C. P., Kang M. H., Watkins A., Houghton P. J., Smith M. A., Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatric Blood & Cancer 2010 55 6 1126 1133 2-s2.0-77958598570 10.1002/pbc.22712
19. Carol H., Houghton P. J., Morton C. L., Kolb E. A., Gorlick R., Reynolds C. P., Kang M. H., Maris J. M., Keir S. T., Watkins A., Smith M. A., Lock R. B., Initial testing of topotecan by the pediatric preclinical testing program. Pediatric Blood & Cancer 2010 54 5 707 715 2-s2.0-77950470724 10.1002/pbc.22352
20. Keshelava N., Houghton P. J., Morton C. L., Lock R. B., Carol H., Keir S. T., Maris J. M., Reynolds C. P., Gorlick R., Kolb E. A., Wu J., Smith M. A., Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatric Blood & Cancer 2009 53 3 505 508 2-s2.0-67651205908 10.1002/pbc.21988
21. Kolb E. A., Gorlick R., Houghton P. J., Morton C. L., Lock R. B., Tajbakhsh M., Reynolds C. P., Maris J. M., Keir S. T., Billups C. A., Smith M. A., Initial testing of dasatinib by the pediatric preclinical testing program. Pediatric Blood & Cancer 2008 50 6 1198 1206 2-s2.0-42349094624 10.1002/pbc.21368 (Pubitemid 351555544)
22. Houghton P. J., Morton C. L., Gorlick R., Lock R. B., Carol H., Reynolds C. P., Kang M. H., Maris J. M., Keir S. T., Kolb E. A., Wu J., Wozniak A. W., Billups C. A., Rubinstein L., Smith M. A., Stage 2 combination testing of rapamycin with cytotoxic agents by the pediatric preclinical testing program. Molecular Cancer Therapeutics 2010 9 1 101 112 2-s2.0-73949122305 10.1158/1535-7163.MCT-09-0952
23. Aplenc R., Ahern C., Study ADVL0516 Progress Report. Study Committee Progress Report-Children's Oncology Group, August 2009
24. Fouladi M., Furman W. L., Chin T., Freeman B. B. III, Dudkin L., Stewart C. F., Krailo M. D., Speights R., Ingle A. M., Houghton P. J., Wright J., Adamson P. C., Blaney S. M., Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a children's oncology group report. Journal of Clinical Oncology 2006 24 22 3678 3685 2-s2.0-33747065289 10.1200/JCO.2006.06. 4964 (Pubitemid 46630544)
25. Knipstein J., Gore L., Entinostat for treatment of solid tumors and hematologic malignancies. Expert Opinion on Investigational Drugs 2011 20 10 1455 1467 2-s2.0-80052703387 10.1517/13543784.2011.613822
26. Cortes J., Rousselot P., Kim D.-W., Ritchie E., Hamerschlak N., Coutre S., Hochhaus A., Guilhot F., Saglio G., Apperley J., Ottmann O., Shah N., Erben P., Branford S., Agarwal P., Gollerkeri A., Baccarani M., Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007 109 8 3207 3213 2-s2.0-33947356135 10.1182/blood-2006-09-046888 (Pubitemid 46572505)
27. Maki R. G., Wathen J. K., Patel S. R., Priebat D. A., Okuno S. H., Samuels B., Fanucchi M., Harmon D. C., Schuetze S. M., Reinke D., Thall P. F., Benjamin R. S., Baker L. H., Hensley M. L., Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas. Journal of Clinical Oncology 2007 25 19 2755 2763 2-s2.0-34447572873 10.1200/JCO.2006.10.4117 (Pubitemid 47123184)
28. Aplenc R., Blaney S. M., Strauss L. C., Balis F. M., Shusterman S., Ingle A. M., Agrawal S., Sun J., Wright J. J., Adamson P. C., Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. Journal of Clinical Oncology 2011 29 7 839 844 2-s2.0-79952319155 10.1200/JCO.2010.30.7231
29. Choy E., Hornicek F., Macconaill L., Harmon D., Tariq Z., Garraway L., Duan Z., High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer 2011 118 11 2905 2914 2-s2.0-80054081856 10.1002/cncr.26617
30. Hernando E., Charytonowicz E., Dudas M. E., Menendez S., Matushansky I., Mills J., Socci N. D., Behrendt N., Ma L., Maki R. G., Pandolfi P. P., Cordon-Cardo C., The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nature Medicine 2007 13 6 748 753 2-s2.0-34250013899 10.1038/nm1560 (Pubitemid 46889749)
31. Vivanco I., Sawyers C. L., The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nature Reviews Cancer 2002 2 7 489 501 2-s2.0-0036632368 (Pubitemid 37328931)
32. Tomita Y., Morooka T., Hoshida Y., Zhang B., Qiu Y., Nakamichi I., Hamada K., Ueda T., Naka N., Kudawara I., Aozasa K., Reassessment of the 1993 Osaka grading system for localized soft tissue sarcoma in Japan. Anticancer Research 2006 26 6C 4665 4669 2-s2.0-33845933502 (Pubitemid 46032097)
33. Nitschke R., Parkhurst J., Sullivan J., Harris M. B., Bernstein M., Pratt C., Topotecan in pediatric patients with recurrent and progressive solid tumors: a pediatric oncology group phase II study. Journal of Pediatric Hematology/Oncology 1998 20 4 315 318 2-s2.0-0031759531 10.1097/00043426- 199807000-00006 (Pubitemid 28483337)
34. Hijiya N., Stewart C. F., Zhou Y., Campana D., Coustan-Smith E., Rivera G. K., Relling M. V., Pui C.-H., Gajjar A., Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. Cancer 2008 112 9 1983 1991 2-s2.0-42449146087 10.1002/cncr.23395 (Pubitemid 351574074)
35. Metzger M. L., Stewart C. F., Freeman B. B. III, Billups C. A., Hoffer F. A., Wu J., Coppes M. J., Grant R., Chintagumpala M., Mullen E. A., Alvarado C., Daw N. C., Dome J. S., Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study. Journal of Clinical Oncology 2007 25 21 3130 3136 2-s2.0-34547679585 10.1200/JCO.2007.10.9298 (Pubitemid 47218062)
36. Shamash J., Powles T., Mutsvangwa K., Wilson P., Ansell W., Walsh E., Berney D., Stebbing J., Oliver T., A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours. Annals of Oncology 2007 18 5 925 930 2-s2.0-34447337007 10.1093/annonc/mdm002 (Pubitemid 47061293)
37. Daw N. C., Santana V. M., Iacono L. C., Furman W. L., Hawkins D. R., Houghton P. J., Panetta J. C., Gajjar A. J., Stewart C. F., Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. Journal of Clinical Oncology 2004 22 5 829 837 2-s2.0-1542398705 10.1200/JCO.2004.07. 110 (Pubitemid 41103594)
38. Walterhouse D. O., Lyden E. R., Breitfeld P. P., Qualman S. J., Wharam M. D., Meyer W. H., Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a children's oncology group study. Journal of Clinical Oncology 2004 22 8 1398 1403 2-s2.0-2342487374 10.1200/JCO.2004.05.184 (Pubitemid 41103621)
39. Garaventa A., Luksch R., Biasotti S., Severi G., Pizzitola M. R., Viscardi E., Prete A., Mastrangelo S., Podda M., Haupt R., De Bernardi B., A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer 2003 98 11 2488 2494 2-s2.0-0344844485 10.1002/cncr.11797 (Pubitemid 37466665)
40. Kramer K., Kushner B. H., Cheung N.-K. V., Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis. Journal of Pediatric Hematology/Oncology 2003 25 8 601 605 2-s2.0-0042570556 10.1097/00043426- 200308000-00003 (Pubitemid 36959419)
41. Furman W. L., Stewart C. F., Kirstein M., Kepner J. L., Bernstein M. L., Kung F., Vietti T. J., Philip Steuber C., Lee Becton D., Baruchel S., Pratt C., Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a Pediatric Oncology Group study. Journal of Clinical Oncology 2002 20 6 1617 1624 2-s2.0-0037087762 10.1200/JCO.20.6.1617 (Pubitemid 34260543)
42. Rubie H., Geoerger B., Frappaz D., Schmitt A., Leblond P., Ndiaye A., Aerts I., Deley M.-C. L., Gentet J.-C., Paci A., Chastagner P., Dias N., Djafari L., Pasquet M., Chatelut E., Landman-Parker J., Corradini N., Vassal G., Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. European Journal of Cancer 2010 46 15 2763 2770 2-s2.0-77957203514 10.1016/j.ejca.2010.05.004
43. Rodriguez-Galindo C., Crews K. R., Stewart C. F., Furman W., Panetta J. C., Daw N. C., Cain A., Tan M., Houghton P. H., Santana V. M., Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer Chemotherapy and Pharmacology 2006 57 1 15 24 2-s2.0-33644696212
44. van der Graaf W. T., Blay J. Y., Chawla S. P., Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet 2012 379 9829 1879 1886 10.1016/S0140-6736(12)60651-5
45. Kumar S., Mokhtari R. B., Sheikh R., Wu B., Zhang L., Xu P., Man S., Oliveira I. D., Yeger H., Kerbel R. S., Baruchel S., Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clinical Cancer Research 2011 17 17 5656 5667 2-s2.0-80052495441 10.1158/1078-0432.CCR-11-0078
46. Talpaz M., Shah N. P., Kantarjian H., Donato N., Nicoll J., Paquette R., Cortes J., O'Brien S., Nicaise C., Bleickardt E., Blackwood-Chirchir M. A., Iyer V., Chen T.-T., Huang F., Decillis A. P., Sawyers C. L., Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. The New England Journal of Medicine 2006 354 24 2531 2541 2-s2.0-33745102555 10.1056/NEJMoa055229 (Pubitemid 43882349)
47. Smith M. A., Houghton P., A proposal regarding reporting of in vitro testing results. Clinical Cancer Research 2013 19 11 2828 2833 10.1158/1078-0432.CCR-13-0043
48. Gerlinger M., Rowan A. J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., Varela I., Phillimore B., Begum S., McDonald N. Q., Butler A., Jones D., Raine K., Latimer C., Santos C. R., Nohadani M., Eklund A. C., Spencer-Dene B., Clark G., Pickering L., Stamp G., Gore M., Szallasi Z., Downward J., Futreal P. A., Swanton C., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England Journal of Medicine 2012 366 10 883 892 2-s2.0-84857839394 10.1056/NEJMoa1113205